QPTF.F Stock Overview
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Quest PharmaTech Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.015 |
52 Week High | CA$0.048 |
52 Week Low | CA$0.015 |
Beta | 0.70 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -87.29% |
5 Year Change | -83.96% |
Change since IPO | -63.41% |
Recent News & Updates
Recent updates
Shareholder Returns
QPTF.F | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | -2.5% | -3.2% |
1Y | n/a | -3.7% | 19.3% |
Return vs Industry: Insufficient data to determine how QPTF.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how QPTF.F performed against the US Market.
Price Volatility
QPTF.F volatility | |
---|---|
QPTF.F Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: QPTF.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine QPTF.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Madi Madiyalakan | www.questpharmatech.com |
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer.
Quest PharmaTech Inc. Fundamentals Summary
QPTF.F fundamental statistics | |
---|---|
Market cap | US$7.40m |
Earnings (TTM) | -US$15.06m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs QPTF.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
QPTF.F income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$20.66m |
Earnings | -CA$20.66m |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.12 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 1.5% |
How did QPTF.F perform over the long term?
See historical performance and comparison